<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20250328121356&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20250328121356&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 28 Mar 2025 16:13:57 +0000</lastbuilddate>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40147443/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeutic outcomes remain underexplored. We applied single-cell RNA and TCR sequencing (scRNA/TCR-seq) to analyze surgical tumor samples from 234 NSCLC patients post-neoadjuvant chemo-immunotherapy. Analyses revealed five distinct TIME subtypes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 19:S0092-8674(25)00291-0. doi: 10.1016/j.cell.2025.03.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeutic outcomes remain underexplored. We applied single-cell RNA and TCR sequencing (scRNA/TCR-seq) to analyze surgical tumor samples from 234 NSCLC patients post-neoadjuvant chemo-immunotherapy. Analyses revealed five distinct TIME subtypes with varying major pathological response (MPR) rates. MPR patients had elevated levels of FGFBP2<sup>+</sup> NK/NK-like T cells, memory B cells, or effector T cells, while non-MPR patients showed higher CCR8<sup>+</sup> Tregs. T cell clonal expansion analyses unveiled heterogeneity in non-MPR patients, marked by varying expansions of Tex-relevant cells and CCR8<sup>+</sup> Tregs. Precursor exhausted T cells (Texp cells) correlated with recurrence-free survival, identifying a patient subgroup with reduced recurrence risk despite lack of MPR. Our study dissects TIME heterogeneity in response to chemoimmunotherapy, offering insights for NSCLC management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40147443/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40147443</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.018>10.1016/j.cell.2025.03.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40147443</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zedao Liu</dc:creator>
<dc:creator>Zhenlin Yang</dc:creator>
<dc:creator>Junqi Wu</dc:creator>
<dc:creator>Wenjie Zhang</dc:creator>
<dc:creator>Yuxuan Sun</dc:creator>
<dc:creator>Chao Zhang</dc:creator>
<dc:creator>Guangyu Bai</dc:creator>
<dc:creator>Li Yang</dc:creator>
<dc:creator>Hongtao Fan</dc:creator>
<dc:creator>Yawen Chen</dc:creator>
<dc:creator>Lei Zhang</dc:creator>
<dc:creator>Benyuan Jiang</dc:creator>
<dc:creator>Xiaoyan Liu</dc:creator>
<dc:creator>Xiaoshi Ma</dc:creator>
<dc:creator>Wei Tang</dc:creator>
<dc:creator>Chang Liu</dc:creator>
<dc:creator>Yang Qu</dc:creator>
<dc:creator>Lixu Yan</dc:creator>
<dc:creator>Deping Zhao</dc:creator>
<dc:creator>Yilong Wu</dc:creator>
<dc:creator>Shun He</dc:creator>
<dc:creator>Long Xu</dc:creator>
<dc:creator>Lishan Peng</dc:creator>
<dc:creator>Xiaowei Chen</dc:creator>
<dc:creator>Bolun Zhou</dc:creator>
<dc:creator>Liang Zhao</dc:creator>
<dc:creator>Zhangyi Zhao</dc:creator>
<dc:creator>Fengwei Tan</dc:creator>
<dc:creator>Wanting Zhang</dc:creator>
<dc:creator>Dingcheng Yi</dc:creator>
<dc:creator>Xiangjie Li</dc:creator>
<dc:creator>Qianqian Gao</dc:creator>
<dc:creator>Guangjian Zhang</dc:creator>
<dc:creator>Yongjie Wang</dc:creator>
<dc:creator>Minglei Yang</dc:creator>
<dc:creator>Honghao Fu</dc:creator>
<dc:creator>Yongjun Guo</dc:creator>
<dc:creator>Xueda Hu</dc:creator>
<dc:creator>Qingyuan Cai</dc:creator>
<dc:creator>Lu Qi</dc:creator>
<dc:creator>Yufei Bo</dc:creator>
<dc:creator>Hui Peng</dc:creator>
<dc:creator>Zhigang Tian</dc:creator>
<dc:creator>Yunlang She</dc:creator>
<dc:creator>Chang Zou</dc:creator>
<dc:creator>Linnan Zhu</dc:creator>
<dc:creator>Sijin Cheng</dc:creator>
<dc:creator>Yi Zhang</dc:creator>
<dc:creator>Wenzhao Zhong</dc:creator>
<dc:creator>Chang Chen</dc:creator>
<dc:creator>Shugeng Gao</dc:creator>
<dc:creator>Zemin Zhang</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer</dc:title>
<dc:identifier>pmid:40147443</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.018</dc:identifier>
</item>
<item>
<title>Large language models deconstruct the clinical intuition behind diagnosing autism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40147442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>Efforts to use genome-wide assays or brain scans to diagnose autism have seen diminishing returns. Yet the clinical intuition of healthcare professionals, based on longstanding first-hand experience, remains the gold standard for diagnosis of autism. We leveraged deep learning to deconstruct and interrogate the logic of expert clinician intuition from clinical reports to inform our understanding of autism. After pre-training on hundreds of millions of general sentences, we finessed large...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 24:S0092-8674(25)00213-2. doi: 10.1016/j.cell.2025.02.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Efforts to use genome-wide assays or brain scans to diagnose autism have seen diminishing returns. Yet the clinical intuition of healthcare professionals, based on longstanding first-hand experience, remains the gold standard for diagnosis of autism. We leveraged deep learning to deconstruct and interrogate the logic of expert clinician intuition from clinical reports to inform our understanding of autism. After pre-training on hundreds of millions of general sentences, we finessed large language models (LLMs) on >;4,000 free-form health records from healthcare professionals to distinguish confirmed versus suspected autism cases. By introducing an explainability strategy, our extended language model architecture could pin down the most salient single sentences in what drives clinical thinking toward correct diagnoses. Our framework flagged the most autism-critical DSM-5 criteria to be stereotyped repetitive behaviors, special interests, and perception-based behaviors, which challenges today's focus on deficits in social interplay, suggesting necessary revision of long-trusted diagnostic criteria in gold-standard instruments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40147442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40147442</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.025>10.1016/j.cell.2025.02.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40147442</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jack Stanley</dc:creator>
<dc:creator>Emmett Rabot</dc:creator>
<dc:creator>Siva Reddy</dc:creator>
<dc:creator>Eugene Belilovsky</dc:creator>
<dc:creator>Laurent Mottron</dc:creator>
<dc:creator>Danilo Bzdok</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Large language models deconstruct the clinical intuition behind diagnosing autism</dc:title>
<dc:identifier>pmid:40147442</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.025</dc:identifier>
</item>
<item>
<title>Stop Me at Your Own PeRiL: PRL2 Constrains AMPK in the Pressure-Overloaded Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40146805/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 28;136(7):664-666. doi: 10.1161/CIRCRESAHA.124.325806. Epub 2025 Mar 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40146805/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40146805</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325806>10.1161/CIRCRESAHA.124.325806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40146805</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Edoardo Bertero</dc:creator>
<dc:creator>Alessandra Ghigo</dc:creator>
<dc:creator>Pietro Ameri</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Stop Me at Your Own PeRiL: PRL2 Constrains AMPK in the Pressure-Overloaded Heart</dc:title>
<dc:identifier>pmid:40146805</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325806</dc:identifier>
</item>
<item>
<title>Taxing Hearts: &lt;em>;TAX1BP3&lt;/em>; Loss Stirs Up TRPV4 Channels in Arrhythmogenic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40146804/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 28;136(7):685-687. doi: 10.1161/CIRCRESAHA.124.325502. Epub 2025 Mar 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40146804/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40146804</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325502>10.1161/CIRCRESAHA.124.325502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40146804</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sandra Ratnavadivel</dc:creator>
<dc:creator>Afaf Jreije</dc:creator>
<dc:creator>Farah Sheikh</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Taxing Hearts: &lt;em>;TAX1BP3&lt;/em>; Loss Stirs Up TRPV4 Channels in Arrhythmogenic Cardiomyopathy</dc:title>
<dc:identifier>pmid:40146804</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325502</dc:identifier>
</item>
<item>
<title>Biophysical and Biochemical Roles of Shear Stress on Endothelium: A Revisit and New Insights</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40146803/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>Hemodynamic shear stress, the frictional force exerted by blood flow on the endothelium, mediates vascular homeostasis. This review examines the biophysical nature and biochemical effects of shear stress on endothelial cells, with a particular focus on its impact on cardiovascular pathophysiology. Atherosclerosis develops preferentially at arterial branches and curvatures, where disturbed flow patterns are most prevalent. The review also highlights the range of shear stress across diverse human...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 28;136(7):752-772. doi: 10.1161/CIRCRESAHA.124.325685. Epub 2025 Mar 27.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hemodynamic shear stress, the frictional force exerted by blood flow on the endothelium, mediates vascular homeostasis. This review examines the biophysical nature and biochemical effects of shear stress on endothelial cells, with a particular focus on its impact on cardiovascular pathophysiology. Atherosclerosis develops preferentially at arterial branches and curvatures, where disturbed flow patterns are most prevalent. The review also highlights the range of shear stress across diverse human arteries and its temporal variations, including aging-related alterations. This review presents a summary of the critical mechanosensors and flow-sensitive effectors that respond to shear stress, along with the downstream cellular events that they regulate. The review evaluates experimental models for studying shear stress in vitro and in vivo, as well as their potential limitations. The review discusses strategies targeting shear stress, including pharmacological approaches, physiological means, surgical interventions, and gene therapies. Furthermore, the review addresses emerging perspectives in hemodynamic research, including single-cell sequencing, spatial omics, metabolomics, and multiomics technologies. By integrating the biophysical and biochemical aspects of shear stress, this review offers insights into the complex interplay between hemodynamics and endothelial homeostasis at the preclinical and clinical levels.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40146803/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40146803</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">PMC11949231</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325685>10.1161/CIRCRESAHA.124.325685</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40146803</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Chak Kwong Cheng</dc:creator>
<dc:creator>Nanping Wang</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Yu Huang</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Biophysical and Biochemical Roles of Shear Stress on Endothelium: A Revisit and New Insights</dc:title>
<dc:identifier>pmid:40146803</dc:identifier>
<dc:identifier>pmc:PMC11949231</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325685</dc:identifier>
</item>
<item>
<title>Correction to: LncRNA PSR Regulates Vascular Remodeling Through Encoding a Novel Protein Arteridin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40146802/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 28;136(7):e52. doi: 10.1161/RES.0000000000000711. Epub 2025 Mar 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40146802/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40146802</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000711>10.1161/RES.0000000000000711</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40146802</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Junyi Yu</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Jining Yang</dc:creator>
<dc:creator>Ye Zhang</dc:creator>
<dc:creator>Xue Gong</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Nian Cao</dc:creator>
<dc:creator>Zaicheng Xu</dc:creator>
<dc:creator>Miao Tian</dc:creator>
<dc:creator>Peili Yang</dc:creator>
<dc:creator>Qiao Mei</dc:creator>
<dc:creator>Zhi Chen</dc:creator>
<dc:creator>Zhuxin Li</dc:creator>
<dc:creator>Chuanwei Li</dc:creator>
<dc:creator>Xudong Duan</dc:creator>
<dc:creator>Qing Rex Lyu</dc:creator>
<dc:creator>Chen Gao</dc:creator>
<dc:creator>Bing Zhang</dc:creator>
<dc:creator>Yibin Wang</dc:creator>
<dc:creator>Gengze Wu</dc:creator>
<dc:creator>Chunyu Zeng</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: LncRNA PSR Regulates Vascular Remodeling Through Encoding a Novel Protein Arteridin</dc:title>
<dc:identifier>pmid:40146802</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000711</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40146801/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 28;136(7):643-644. doi: 10.1161/RES.0000000000000712. Epub 2025 Mar 27.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40146801/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40146801</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000712>10.1161/RES.0000000000000712</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40146801</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:date>2025-03-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:40146801</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000712</dc:identifier>
</item>
<item>
<title>Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40146800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics technologies have begun revolutionizing our understanding of the molecular mechanisms driving cardiac fibrosis and are providing unprecedented insights into its heterogeneity and progression. This review provides a comprehensive analysis of how techniques-encompassing genomics, epigenomics, transcriptomics,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 28;136(7):773-802. doi: 10.1161/CIRCRESAHA.124.325402. Epub 2025 Mar 27.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics technologies have begun revolutionizing our understanding of the molecular mechanisms driving cardiac fibrosis and are providing unprecedented insights into its heterogeneity and progression. This review provides a comprehensive analysis of how techniques-encompassing genomics, epigenomics, transcriptomics, proteomics, and metabolomics-are providing insight into our understanding of cardiac fibrosis. Genomic studies have identified novel genetic variants and regulatory networks associated with fibrosis susceptibility and progression, and single-cell transcriptomics has unveiled distinct cardiac fibroblast subpopulations with unique molecular signatures. Epigenomic profiling has revealed dynamic chromatin modifications controlling fibroblast activation states, and proteomic analyses have identified novel biomarkers and potential therapeutic targets. Metabolomic studies have uncovered important alterations in cardiac energetics and substrate utilization during fibrotic remodeling. The integration of these multi-omic data sets has led to the identification of previously unrecognized pathogenic mechanisms and potential therapeutic targets, including cell-type-specific interventions and metabolic modulators. We discuss how these advances are driving the development of precision medicine approaches for cardiac fibrosis while highlighting current challenges and future directions in translating multi-omic insights into effective therapeutic strategies. This review provides a systems-level perspective on cardiac fibrosis that may inform the development of more effective, personalized therapeutic approaches for heart failure and related cardiovascular diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40146800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40146800</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">PMC11949229</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325402>10.1161/CIRCRESAHA.124.325402</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40146800</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Rachad Ghazal</dc:creator>
<dc:creator>Min Wang</dc:creator>
<dc:creator>Duan Liu</dc:creator>
<dc:creator>Daniel J Tschumperlin</dc:creator>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure</dc:title>
<dc:identifier>pmid:40146800</dc:identifier>
<dc:identifier>pmc:PMC11949229</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325402</dc:identifier>
</item>
<item>
<title>Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40140695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 26. doi: 10.1038/s41569-025-01149-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40140695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40140695</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01149-8>10.1038/s41569-025-01149-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40140695</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling</dc:title>
<dc:identifier>pmid:40140695</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01149-8</dc:identifier>
</item>
<item>
<title>Ventricular Wall Stress in Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):e133. doi: 10.1016/j.jacc.2024.08.091.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139898</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.091>10.1016/j.jacc.2024.08.091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139898</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kazuo Komamura</dc:creator>
<dc:creator>Hiroshi Miyake</dc:creator>
<dc:creator>Koichi Kobayashi</dc:creator>
<dc:creator>Ryoji Ishiki</dc:creator>
<dc:creator>Mitsunori Iwase</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Wall Stress in Aortic Stenosis</dc:title>
<dc:identifier>pmid:40139898</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.091</dc:identifier>
</item>
<item>
<title>Reply: Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):e131. doi: 10.1016/j.jacc.2025.01.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139897</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.023>10.1016/j.jacc.2025.01.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139897</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lisa E Vaughan</dc:creator>
<dc:creator>Vesna D Garovic</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:40139897</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.023</dc:identifier>
</item>
<item>
<title>Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):e129-e130. doi: 10.1016/j.jacc.2024.11.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139896</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.053>10.1016/j.jacc.2024.11.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139896</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ruyi Zhou</dc:creator>
<dc:creator>Senlin Ye</dc:creator>
<dc:creator>Jinli Liu</dc:creator>
<dc:creator>Lincheng Duan</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:40139896</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.053</dc:identifier>
</item>
<item>
<title>Using Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1376-1378. doi: 10.1016/j.jacc.2025.01.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139895</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.005>10.1016/j.jacc.2025.01.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139895</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>George Goshua</dc:creator>
<dc:creator>Merilyn Varghese</dc:creator>
<dc:creator>Satoko Ito</dc:creator>
<dc:creator>Ankur Pandya</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency</dc:title>
<dc:identifier>pmid:40139895</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.005</dc:identifier>
</item>
<item>
<title>Albuminuria: A Marker of Adverse Kidney Outcomes in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139894/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1372-1375. doi: 10.1016/j.jacc.2025.01.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139894/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139894</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.025>10.1016/j.jacc.2025.01.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139894</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sophie E Claudel</dc:creator>
<dc:creator>Insa M Schmidt</dc:creator>
<dc:creator>Sushrut S Waikar</dc:creator>
<dc:creator>Ashish Verma</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Albuminuria: A Marker of Adverse Kidney Outcomes in Heart Failure</dc:title>
<dc:identifier>pmid:40139894</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.025</dc:identifier>
</item>
<item>
<title>The Importance of Remnant Cholesterol in PAD: Hidden in Plain Sight</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1369-1371. doi: 10.1016/j.jacc.2025.01.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139893</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.027>10.1016/j.jacc.2025.01.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139893</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Importance of Remnant Cholesterol in PAD: Hidden in Plain Sight</dc:title>
<dc:identifier>pmid:40139893</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.027</dc:identifier>
</item>
<item>
<title>Elevated Remnant and LDL Cholesterol and the Risk of Peripheral Artery Disease: A Mendelian Randomization Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139892/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Elevated remnant cholesterol had a causal effect on risk of PAD even after accounting for elevated LDL cholesterol, whereas most of the causal effect of elevated LDL cholesterol on risk of PAD was dependent on simultaneously elevated remnant cholesterol. These results indicate that remnant cholesterol may be the major cholesterol fraction responsible for increased risk of PAD. Future studies should investigate the biological mechanisms behind these findings to find improved...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1353-1368. doi: 10.1016/j.jacc.2024.12.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Elevated remnant cholesterol and low-density lipoprotein (LDL) cholesterol both increase the risk of coronary artery disease (CAD), but it is not known if the same is true for peripheral artery disease (PAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study tested the hypothesis that elevated remnant cholesterol and LDL cholesterol, each independent of the other, have causal effects on risk of PAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors constructed genetic scores from variants near genes known to directly affect levels of remnant cholesterol and LDL cholesterol, identified through a genome-wide association study of individuals in the UK Biobank. Univariable (remnant cholesterol and LDL cholesterol genetic scores separately) and multivariable (remnant cholesterol and LDL cholesterol genetic scores combined) Mendelian randomization were used to estimate the causal effects of higher remnant cholesterol and LDL cholesterol levels on ORs for PAD (n = 38,414 cases and 758,308 controls) and CAD (n = 221,445 cases and 770,615 controls).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Increments in remnant and LDL genetic scores corresponding to 1 mmol/L (39 mg/dL) higher remnant and LDL cholesterol, respectively, were associated with univariable ORs for PAD of 2.72 (95% CI: 2.10-3.52) and 1.37 (95% CI: 1.25-1.51); corresponding multivariable ORs were 2.16 (95% CI: 1.49-3.12) and 1.14 (95% CI: 1.00-1.30). For CAD, corresponding univariable ORs were 2.92 (95% CI: 2.34-3.64) and 1.67 (95% CI: 1.56-1.79), whereas multivariable ORs were 1.86 (95% CI: 1.39-2.47) and 1.44 (95% CI: 1.29-1.60). Scaled to 1 SD increments in remnant cholesterol and LDL cholesterol, corresponding univariable ORs were 1.37 (95% CI: 1.27-1.49) and 1.29 (95% CI: 1.20-1.39) for PAD, and 1.40 (95% CI: 1.31-1.51) and 1.51 (95% CI: 1.43-1.59) for CAD; corresponding multivariable ORs were 1.28 (95% CI: 1.14-1.43) and 1.11 (95% CI: 1.00-1.23) for PAD, and 1.22 (95% CI: 1.11-1.33) and 1.34 (95% CI: 1.23-1.46) for CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Elevated remnant cholesterol had a causal effect on risk of PAD even after accounting for elevated LDL cholesterol, whereas most of the causal effect of elevated LDL cholesterol on risk of PAD was dependent on simultaneously elevated remnant cholesterol. These results indicate that remnant cholesterol may be the major cholesterol fraction responsible for increased risk of PAD. Future studies should investigate the biological mechanisms behind these findings to find improved therapies for prevention and treatment of PAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139892/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139892</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.033>10.1016/j.jacc.2024.12.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139892</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Nilsson Wadström</dc:creator>
<dc:creator>Maria Carolina Borges</dc:creator>
<dc:creator>Anders Berg Wulff</dc:creator>
<dc:creator>George Davey Smith</dc:creator>
<dc:creator>Eleanor Sanderson</dc:creator>
<dc:creator>Børge Grønne Nordestgaard</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Elevated Remnant and LDL Cholesterol and the Risk of Peripheral Artery Disease: A Mendelian Randomization Study</dc:title>
<dc:identifier>pmid:40139892</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.033</dc:identifier>
</item>
<item>
<title>Evidence of Benefit for Chronic Total Occlusion Revascularization From ISCHEMIA: New Road or Dead End?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1350-1352. doi: 10.1016/j.jacc.2025.02.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139891</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.011>10.1016/j.jacc.2025.02.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139891</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ziad A Ali</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>John A Bittl</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evidence of Benefit for Chronic Total Occlusion Revascularization From ISCHEMIA: New Road or Dead End?</dc:title>
<dc:identifier>pmid:40139891</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.011</dc:identifier>
</item>
<item>
<title>Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the ISCHEMIA trial, the risks and benefits of INV compared with CON were similar among patients with and without CCTA-determined CTO (more frequent procedural MI, less frequent spontaneous MI, and significantly improved angina and dyspnea-related quality of life). In an observational comparison, successful CTO REV was associated with a high probability of lower CV death or MI (driven by lower MI) compared with CON. (International Study of Comparative Health Effectiveness With...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1335-1349. doi: 10.1016/j.jacc.2025.01.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Randomized trials of chronic total occlusion (CTO) revascularization vs medical therapy have yielded inconsistent results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate outcomes with an initial invasive strategy (INV) vs an initial conservative strategy (CON) in patients with coronary computed tomographic angiography (CCTA)-determined CTO in the ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants in ISCHEMIA who underwent CCTA evaluated for CTO by the core laboratory (3,113 of 5,179 randomized patients [60%]) were categorized into subgroups with (100% stenosis) and without (&lt;100% stenosis) CTO. Primary analysis compared outcomes in those randomized to INV vs CON using an intention-to-treat approach. Secondary analyses compared outcomes using inverse probability weighting to model successful CTO revascularization (REV) in all INV participants vs CON participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 3,113 CCTA-evaluable participants, 1,470 had at least 1 CTO (752 INV and 718 CON). INV did not reduce cardiovascular (CV) death or myocardial infarction (MI) (5-year difference -3.5%; 95% CI: -7.8% to 0.8%) and resulted in more procedural MIs (2.5%; 95% CI: 1.0%-4.0%) but fewer spontaneous MIs (-6.3%; 95% CI: -9.7% to -3.2%) than CON. CTO REV modeled across INV had a high probability (>;90%) of any lower CV death or MI, MI, spontaneous MI, unstable angina, and heart failure counterbalanced by a higher rate of procedural MI. CTO REV significantly improved angina-related quality of life (mean difference 4.6 points), Rose Dyspnea Scale score (rescaled) (mean difference 5.3 points), and EQ-5D visual analog scale score (4.6 points).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the ISCHEMIA trial, the risks and benefits of INV compared with CON were similar among patients with and without CCTA-determined CTO (more frequent procedural MI, less frequent spontaneous MI, and significantly improved angina and dyspnea-related quality of life). In an observational comparison, successful CTO REV was associated with a high probability of lower CV death or MI (driven by lower MI) compared with CON. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139890</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.029>10.1016/j.jacc.2025.01.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139890</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>G B John Mancini</dc:creator>
<dc:creator>Jonathan Leipsic</dc:creator>
<dc:creator>Mathew J Budoff</dc:creator>
<dc:creator>Yifan Xu</dc:creator>
<dc:creator>Rebecca Anthopolos</dc:creator>
<dc:creator>Emmanouil S Brilakis</dc:creator>
<dc:creator>Aeshita Dwivedi</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Phil G Jones</dc:creator>
<dc:creator>Yoon Joo Cho</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Cameron J Hague</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Ahmed Elghamaz</dc:creator>
<dc:creator>Rajesh Goplan Nair</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Gilbert Gosselin</dc:creator>
<dc:creator>Subhash Banerjee</dc:creator>
<dc:creator>Hristo Pejkov</dc:creator>
<dc:creator>Steven Lindsay</dc:creator>
<dc:creator>J Aaron Grantham</dc:creator>
<dc:creator>David O Williams</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Sean M O'Brien</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:40139890</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.029</dc:identifier>
</item>
<item>
<title>Using Joint Models to Find What Worked Best in ISCHEMIA: Setting a New Standard</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1332-1334. doi: 10.1016/j.jacc.2025.02.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139889</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.003>10.1016/j.jacc.2025.02.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139889</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>John A Bittl</dc:creator>
<dc:creator>Haiqun Lin</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Joint Models to Find What Worked Best in ISCHEMIA: Setting a New Standard</dc:title>
<dc:identifier>pmid:40139889</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.003</dc:identifier>
</item>
<item>
<title>Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1317-1331. doi: 10.1016/j.jacc.2025.01.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Guideline-directed medical therapy (GDMT) with multiple risk factor goals is recommended for patients with chronic coronary disease (CCD), yet achieving all GDMT goals is uncommon. The relative importance of these goals and timing of their attainment on cardiovascular events is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to describe the relationship between achieving specific GDMT goals, when they are achieved, and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was an observational study of participants with CCD in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial. The primary outcome was cardiovascular (CV) death or myocardial infarction (MI). GDMT goals were systolic blood pressure (SBP) &lt;130 mm Hg, low-density lipoprotein cholesterol &lt;70 mg/dL, not smoking, and antiplatelet therapy. Frequency of GDMT goals met at baseline and during follow-up is described. Bayesian joint modeling for longitudinal goal status and time-to-event analyses characterized the relative importance of specific GDMT goal attainment and timing with CV death/MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: All 5,179 ISCHEMIA participants were included. Among 4,914 participants with complete data on all 4 GDMT goals at baseline, 386 (9%), 2,073 (42%), 1,843 (38%), and 612 (12%) met 0-1, 2, 3, and 4 GDMT goals, respectively. The 4-year cumulative event rate for CV death/MI was highest for participants who attained no GDMT goals (24.5%; 95% credible interval [CrI]: 13.5%-42.2%) and lowest for those who attained all goals at baseline and remained at goal during follow-up (8.7%; 95% CrI: 6.7%-10.9%). SBP goal attainment was associated with a significant absolute event reduction in CV death/MI (-5.1%; 95% CrI: -11.3% to -1.0%), followed by antiplatelet therapy (-11.2%; 95% CrI: -29.1% to 0.8%), achieving low-density lipoprotein cholesterol &lt;70 mg/dL (-2.0%; 95% CrI: -6.0% to 2.4%), and not smoking (-1.7%; 95% CrI: -9.3% to 4.2%). Ten millimeters of mercury lower SBP during follow-up was associated with 10% relative risk reduction of CV death/MI (RR [relative risk] = 0.90; 95% CrI: 0.82-0.98), after adjusting for other GDMT goals and baseline characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139888</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.028>10.1016/j.jacc.2025.01.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139888</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Jonathan D Newman</dc:creator>
<dc:creator>Rebecca Anthopolos</dc:creator>
<dc:creator>Ying Lu</dc:creator>
<dc:creator>Susanna Stevens</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Jason Linefsky</dc:creator>
<dc:creator>Rajesh G Nair</dc:creator>
<dc:creator>Olga Bockeria</dc:creator>
<dc:creator>Gilbert Gosselin</dc:creator>
<dc:creator>Gian P Perna</dc:creator>
<dc:creator>Elena Demchenko</dc:creator>
<dc:creator>David Foo</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>Mary Ann Champagne</dc:creator>
<dc:creator>Christie Ballantyne</dc:creator>
<dc:creator>Peter McCullough</dc:creator>
<dc:creator>Jose Luis Lopez-Sendon</dc:creator>
<dc:creator>Frank Rockhold</dc:creator>
<dc:creator>Frank Harrell</dc:creator>
<dc:creator>Yves Rosenberg</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:40139888</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.028</dc:identifier>
</item>
<item>
<title>Implementing ECG-AI in Clinical Care: From Pixel to Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250328121356&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1314-1316. doi: 10.1016/j.jacc.2025.02.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250328121356&v=2.18.0.post9+e462414">40139887</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.008>10.1016/j.jacc.2025.02.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139887</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Minjae Yoon</dc:creator>
<dc:creator>Seng Chan You</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implementing ECG-AI in Clinical Care: From Pixel to Practice</dc:title>
<dc:identifier>pmid:40139887</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.008</dc:identifier>
</item>





























</channel>
</rss>